{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:33Z","timestamp":1789469133304,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bursa Uludag University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute graft-versus-host disease (aGVHD) is one of the most fatal yet preventable complications of hematopoietic stem cell transplantation (HSCT). Identifying optimal cyclosporine (CsA) blood level thresholds is particularly important in patients receiving CsA-based prophylaxis; however, cut-off values remain unclear. This retrospective study evaluated 120 patients with acute leukemia (64% acute myeloid leukemia [AML], 36% acute lymphoblastic leukemia [ALL]) who underwent allogeneic HSCT (AHSCT) between June 2011 and March 2021. CsA combined with methotrexate was used for GVHD prophylaxis. Statistical analyses included ROC analysis to determine optimal cut-off values and logistic regression to identify independent risk factors for aGVHD. aGVHD developed in 34 patients (28%), with a median onset at day 48. ROC curve analysis identified a CsA cut-off level of 274\u00a0\u00b5g\/L during months 1\u20132, with an AUC of 0.697 (95% Confidence Interval [CI]: 0.574\u20130.820,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005), sensitivity of 77.3%, and specificity of 63%. In multivariate analysis, higher CsA levels during months 1\u20132 (Odds Ratio [OR]\u2009=\u20090.990, 95% CI 0.981\u20131.000;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039) and pre-transplant steroid use (OR\u2009=\u20090.284, 95% CI 0.094\u20130.860;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026) were independently associated with reduced risk of aGVHD. No universally accepted cut-off value of CsA levels has been defined to date, and our findings suggest that maintaining levels above 274\u00a0\u00b5g\/L during the first 1\u20132 months post-transplant is critical to reduce aGVHD risk.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07131-9","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:45:11Z","timestamp":1781509511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining a critical therapeutic window: cyclosporine exposure in months 1\u20132 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-634X","authenticated-orcid":false,"given":"Neslihan Hazel","family":"\u00d6n\u00fcr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-7398","authenticated-orcid":false,"given":"Vildan","family":"\u00d6zkocaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-134X","authenticated-orcid":false,"given":"Fahir","family":"\u00d6zkalemka\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"S1","key":"7131_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00005-016-0446-2","volume":"64","author":"F Mrazek","year":"2016","unstructured":"Mrazek F, Schneiderova P, Kriegova E et al (2016) Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study. Arch Immunol Ther Exp (Warsz) 64(S1):55\u201361. https:\/\/doi.org\/10.1007\/s00005-016-0446-2","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"7131_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jare.2014.11.001","volume":"6","author":"HK Mahmoud","year":"2015","unstructured":"Mahmoud HK, Elhaddad AM, Fahmy OA et al (2015) Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders. J Adv Res 6(3):449\u2013458. https:\/\/doi.org\/10.1016\/j.jare.2014.11.001","journal-title":"J Adv Res"},{"key":"7131_CR3","doi-asserted-by":"publisher","unstructured":"Michniacki TF, Choi SW, Peltier DC (2021) Immune suppression in allogeneic hematopoietic stem cell transplantation. 209\u2013243. https:\/\/doi.org\/10.1007\/164_2021_544","DOI":"10.1007\/164_2021_544"},{"issue":"4","key":"7131_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00277-018-3577-1","volume":"98","author":"M Bianchi","year":"2019","unstructured":"Bianchi M, Heim D, Lengerke C et al (2019) Cyclosporine levels > 195 \u00b5g\/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann Hematol 98(4):971\u2013977. https:\/\/doi.org\/10.1007\/s00277-018-3577-1","journal-title":"Ann Hematol"},{"issue":"22","key":"7131_CR5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR (2017) Acute Graft-versus-Host Disease \u2014 Biologic Process, Prevention, and Therapy. N Engl J Med 377(22):2167\u20132179. https:\/\/doi.org\/10.1056\/NEJMra1609337","journal-title":"N Engl J Med"},{"issue":"9674","key":"7131_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550\u20131561. https:\/\/doi.org\/10.1016\/S0140-6736(09)60237-3","journal-title":"Lancet"},{"key":"7131_CR7","doi-asserted-by":"publisher","unstructured":"Alada\u011f E, Kelkitli E, G\u00f6ker H (2020) Acute graft-versus-host disease: a brief review. Turkish J Hematol 37(1). https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2019.0157","DOI":"10.4274\/tjh.galenos.2019.2019.0157"},{"key":"7131_CR8","unstructured":"Boelens JJBFGL et al (2024) Hematopoietic cell transplantation and cellular therapies. In: Sureda A CSGR ed. The EBMT Handbook: hematopoietic cell transplantation and cellular therapies. 8th edition. Springer, Cham (CH)"},{"issue":"12","key":"7131_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Whitehead J et al (1986) Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia. N Engl J Med 314(12):729\u2013735. https:\/\/doi.org\/10.1056\/NEJM198603203141201","journal-title":"N Engl J Med"},{"key":"7131_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/620682","volume":"2014","author":"I Garc\u00eda Cadenas","year":"2014","unstructured":"Garc\u00eda Cadenas I, Valcarcel D, Martino R et al (2014) Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. Mediators Inflamm 2014:1\u20137. https:\/\/doi.org\/10.1155\/2014\/620682","journal-title":"Mediators Inflamm"},{"issue":"6","key":"7131_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4103\/0973-1482.157338","volume":"13","author":"A Gupta","year":"2017","unstructured":"Gupta A, Punatar S, Gawande J, Mathew L, Kannan S, Khattry N (2017) Analysis of factors affecting initial cyclosporine level and its impact on post transplant outcomes in acute leukemia. J Cancer Res Ther 13(6):981\u2013988. https:\/\/doi.org\/10.4103\/0973-1482.157338","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"7131_CR12","first-page":"305","volume":"13","author":"S Zeighami","year":"2014","unstructured":"Zeighami S, Hadjibabaie M, Ashouri A et al (2014) Assessment of cyclosporine serum concentrations on the incidence of acute graft versus host disease post hematopoietic stem cell transplantation. Iran J Pharm Res 13(1):305\u2013312","journal-title":"Iran J Pharm Res"},{"issue":"5","key":"7131_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bjhh.2014.03.010","volume":"36","author":"JB da Silva","year":"2014","unstructured":"da Silva JB, de Melo Lima MH, Secoli SR (2014) Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review. Rev Bras Hematol Hemoter 36(5):363\u2013368. https:\/\/doi.org\/10.1016\/j.bjhh.2014.03.010","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"5","key":"7131_CR14","first-page":"461","volume":"13","author":"M Mehdizadeh","year":"2015","unstructured":"Mehdizadeh M, Hajifathali A, Tafazoli A (2015) Drug Utilization Evaluation of Cyclosporine in Allogeneic Hematopoietic Stem Cell Transplantation. Exp Clin Transpl 13(5):461\u2013466","journal-title":"Exp Clin Transpl"},{"key":"7131_CR15","unstructured":"Oxford University Hospitals NHS Foundation Trust (2023) Ciclosporin (CsA) for Patients Receiving Allogeneic Blood and Marrow Transplantation. Oxford Haematology. https:\/\/nssg.oxford-haematology.org.uk\/bmt\/clin-man\/B-2-19-ciclosporin-for-patients-allogenic-bmt.pdf"},{"issue":"12","key":"7131_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jtct.2024.09.017","volume":"30","author":"R Iftikhar","year":"2024","unstructured":"Iftikhar R, DeFilipp Z, DeZern AE et al (2024) Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther 30(12):1155\u20131170. https:\/\/doi.org\/10.1016\/j.jtct.2024.09.017","journal-title":"Transpl Cell Ther"},{"key":"7131_CR17","unstructured":"Boelens JJ, Bonifazi F, Gj\u00e6rde LK et al (2024) CSA\/MTX for GVHD prophylaxis. In: Sureda A; Corbacioglu S; Greco R; ed. The EBMT Handbook: hematopoietic cell transplantation and cellular therapies. 8th ed. Springer; Accessed August 25, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK608285\/table\/ch26.Tab1\/?report=objectonly"},{"issue":"1","key":"7131_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/asheducation-2015.1.215","volume":"2015","author":"MRM van den Brink","year":"2015","unstructured":"van den Brink MRM, Velardi E, Perales MA (2015) Immune reconstitution following stem cell transplantation. Hematology 2015(1):215\u2013219. https:\/\/doi.org\/10.1182\/asheducation-2015.1.215","journal-title":"Hematology"},{"issue":"4","key":"7131_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00281-008-0132-5","volume":"30","author":"J Storek","year":"2008","unstructured":"Storek J, Geddes M, Khan F et al (2008) Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 30(4):425\u2013437. https:\/\/doi.org\/10.1007\/s00281-008-0132-5","journal-title":"Semin Immunopathol"},{"issue":"3","key":"7131_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJM199501193320303","volume":"332","author":"CL Mackall","year":"1995","unstructured":"Mackall CL, Fleisher TA, Brown MR et al (1995) Age, Thymopoiesis, and CD4\u2009+\u2009T-Lymphocyte Regeneration after Intensive Chemotherapy. N Engl J Med 332(3):143\u2013149. https:\/\/doi.org\/10.1056\/NEJM199501193320303","journal-title":"N Engl J Med"},{"issue":"4","key":"7131_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1172\/JCI22492","volume":"115","author":"FT Hakim","year":"2005","unstructured":"Hakim FT, Memon SA, Cepeda R et al (2005) Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 115(4):930\u2013939. https:\/\/doi.org\/10.1172\/JCI22492","journal-title":"J Clin Invest"},{"issue":"9","key":"7131_CR22","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00277-023-05332-0","volume":"102","author":"F Lin","year":"2023","unstructured":"Lin F, Dong X, Zhang Y et al (2023) Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia. Ann Hematol 102(9):2589\u20132598. https:\/\/doi.org\/10.1007\/s00277-023-05332-0","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07131-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07131-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:43:10Z","timestamp":1789465390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07131-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7131"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07131-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study complied with the principles of the Declaration of Helsinki and was approved by the Bursa Uludag University Clinical Research Ethics Committee (Approval No: 2022-4\/49).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed informed consent regarding publishing their data.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"388"}}